{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:02Z","timestamp":1790351462668,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41375-025-02592-9","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:53:41Z","timestamp":1744188821000},"page":"1124-1134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-029X","authenticated-orcid":false,"given":"Fabian","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-0997","authenticated-orcid":false,"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-0478","authenticated-orcid":false,"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-3730","authenticated-orcid":false,"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. W. M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gessami","family":"Sanchez-Olle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Pognan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3338-304X","authenticated-orcid":false,"given":"Meng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-4032","authenticated-orcid":false,"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2592_CR1","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2592_CR2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91:252\u201365.","journal-title":"Am J Hematol"},{"key":"2592_CR3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"2592_CR4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353.","journal-title":"Leukemia"},{"key":"2592_CR5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"2592_CR6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"2592_CR7","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"2592_CR8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-137393","volume":"136","author":"TH Br\u00fcmmendorf","year":"2020","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre PD, et al. Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): final 5-year results from the Bfore trial. Blood. 2020;136:41\u20132.","journal-title":"Blood"},{"key":"2592_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Br\u00fcmmendorf","year":"2015","unstructured":"Br\u00fcmmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvilli\u00e9 L, Pavlov D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168:69\u201381.","journal-title":"Br J Haematol"},{"key":"2592_CR10","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Br\u00fcmmendorf TH, Smith BD, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125\u201337.","journal-title":"Leukemia"},{"key":"2592_CR11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood"},{"key":"2592_CR12","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042\u201350.","journal-title":"Blood"},{"key":"2592_CR13","doi-asserted-by":"crossref","unstructured":"Busque L, Harnois M, Szuber N, Delage R, Mollica L, Olney H, et al. Qu\u00e9bec CML Research Group analysis of treatment patterns in chronic myelogenous leukemia: switching is driven by intolerance and similar across tyrosine kinase inhibitors and lines of treatment. Oral presentation at: EHA2022 Hybrid Congress; June 9-17, 2022; Vienna, Austria. Abstract S159.","DOI":"10.1097\/01.HS9.0000843528.26169.66"},{"key":"2592_CR14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","volume":"25","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011;25:981\u201395.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2592_CR15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O\u2019Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am. 2017;31:589\u2013612.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2592_CR16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","volume":"15","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015;15:323\u201334.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2592_CR17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.htct.2018.11.005","volume":"41","author":"GR Bosi","year":"2019","unstructured":"Bosi GR, Fogliatto LM, Costa TEV, Grokoski KC, Pereira MP, Bugs N, et al. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?. Hematol Transfus Cell Ther. 2019;41:222\u20138.","journal-title":"Hematol Transfus Cell Ther"},{"key":"2592_CR18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.","journal-title":"J Hematol Oncol"},{"key":"2592_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-022-03446-1","volume":"117","author":"ZN Ozdemir","year":"2023","unstructured":"Ozdemir ZN, Kilicaslan NA, Yilmaz M, Eskazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol. 2023;117:3\u201315.","journal-title":"Int J Hematol"},{"key":"2592_CR20","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med"},{"key":"2592_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:43\u201369.","journal-title":"J Natl Compr Canc Netw"},{"key":"2592_CR22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","volume":"38","author":"S Soverini","year":"2014","unstructured":"Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38:10\u201320.","journal-title":"Leuk Res"},{"key":"2592_CR23","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120\u201335.","journal-title":"J Med Chem"},{"key":"2592_CR24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733\u20137.","journal-title":"Nature"},{"key":"2592_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98. 106458.","journal-title":"Leuk Res"},{"key":"2592_CR26","unstructured":"Scemblix [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp."},{"key":"2592_CR27","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315\u201326.","journal-title":"N Engl J Med"},{"key":"2592_CR28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"MJ Mauro","year":"2023","unstructured":"Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37:1048\u201359.","journal-title":"Leukemia"},{"key":"2592_CR29","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341.","journal-title":"Blood"},{"key":"2592_CR30","unstructured":"Scemblix [summary of product characteristics]. Dublin, Ireland: Novartis Europharm Limited; August 2022."},{"key":"2592_CR31","unstructured":"Novartis. Novartis Scemblix\u00ae shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in phase III trial for newly diagnosed patients with chronic myeloid leukemia. 2024. https:\/\/www.novartis.com\/news\/media-releases\/novartis-scemblix-shows-superior-major-molecular-response-mmr-rates-vs-standard-care-tkis-phase-iii-trial-newly-diagnosed-patients-chronic-myeloid-leukemia."},{"key":"2592_CR32","doi-asserted-by":"crossref","first-page":"9606","DOI":"10.1182\/blood-2022-169828","volume":"140","author":"AM Leyte-Vidal","year":"2022","unstructured":"Leyte-Vidal AM, Shah NP. Select P-loop mutants in BCR::ABL1 confer moderate to high degrees of resistance to asciminib. Blood. 2022;140:9606\u20137.","journal-title":"Blood"},{"key":"2592_CR33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36:431\u201343.e5.","journal-title":"Cancer Cell"},{"key":"2592_CR34","volume":"20","author":"HJG Lindstrom","year":"2020","unstructured":"Lindstrom HJG, Friedman R. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib. BMC Cancer. 2020;20:397.","journal-title":"BMC Cancer"},{"key":"2592_CR35","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","volume":"38","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u22651 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024;38:1522\u201333.","journal-title":"Leukemia"},{"key":"2592_CR36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617\u201326.","journal-title":"Leukemia"},{"key":"2592_CR37","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:885\u201398.","journal-title":"N Engl J Med"},{"key":"2592_CR38","doi-asserted-by":"crossref","unstructured":"Mauro M, Kim D-W, Cortes J, R\u00e9a D, Hughes TP, Minami H, et al. Combination of asciminib plus nilotinib (NIL) or dasatinib (DAS) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study. Oral presentation at: 24th EHA Congress; June 13-16, 2019; Amsterdam, the Netherlands. Abstract S884.","DOI":"10.1097\/01.HS9.0000561816.04574.8b"},{"key":"2592_CR39","doi-asserted-by":"crossref","unstructured":"Cortes J, Lang F, Kim D-W, R\u00e9a D, Mauro MJ, Minami H, et al. Combination therapy using asciminib plus imatinib (IMA) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study. Oral presentation at: 24th EHA Congress; June 13-16, 2019; Amsterdam, the Netherlands. Abstract S883.","DOI":"10.1097\/01.HS9.0000561812.22500.d8"},{"key":"2592_CR40","unstructured":"ClinicalTrials.gov. A phase I study of oral asciminib (ABL001) in patients with CML or Ph+ ALL. 2024. https:\/\/clinicaltrials.gov\/study\/NCT02081378."},{"key":"2592_CR41","unstructured":"Hochhaus A, et al. Presented at: 65th ASH Annual Meeting & Exposition; December 9-12, 2023; San Diego, CA, and virtual. Oral 450."},{"key":"2592_CR42","unstructured":"Cortes JE, et al. Oral presentation at: 26th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy; September 27-29, 2024; Prague, Czech Republic."},{"key":"2592_CR43","doi-asserted-by":"crossref","unstructured":"Cortes JE, Lang F, R\u00e9a D, Hochhaus A, Breccia M, Yeow Tee G, et al. Asciminib (ASC) in combination with imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome\u2013positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph+ CML-CP\/AP): final results from the asciminib phase 1 study. Oral presentation at: 65th American Society of Hematology Annual Meeting; December 9-12, 2023; San Diego, CA, and virtual. Oral 868.","DOI":"10.1182\/blood-2023-189270"},{"key":"2592_CR44","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G, Garc\u00eda-Guti\u00e9rrez V, R\u00e9a D, Janssen J, et al. Expert opinion\u2014management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495\u2013502.","journal-title":"Leukemia"},{"key":"2592_CR45","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41\u201351.","journal-title":"Ann Oncol"},{"key":"2592_CR46","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","volume":"29","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823\u201331.","journal-title":"Leukemia"},{"key":"2592_CR47","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406.","journal-title":"Leukemia"},{"key":"2592_CR48","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, R\u00e9a D, le Coutre P. Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood. 2015;125:901\u20136.","journal-title":"Blood"},{"key":"2592_CR49","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648\u201371.","journal-title":"Leukemia"},{"key":"2592_CR50","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garcia-Gutierrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Hern\u00e1ndez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:603.","journal-title":"Front Oncol"},{"key":"2592_CR51","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"2592_CR52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","volume":"164","author":"MW Deininger","year":"2014","unstructured":"Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, et al. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014;164:223\u201332.","journal-title":"Br J Haematol"},{"key":"2592_CR53","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","volume":"123","author":"NP Shah","year":"2014","unstructured":"Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Br\u00fcmmendorf TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317\u201324.","journal-title":"Blood"},{"key":"2592_CR54","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.2020006911","volume":"136","author":"J Cortes","year":"2020","unstructured":"Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136:2507\u201312.","journal-title":"Blood"},{"key":"2592_CR55","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of asciminib in combination with imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). 2024. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03578367."},{"key":"2592_CR56","doi-asserted-by":"crossref","unstructured":"Hughes TP, Saglio G, Geissler J, Kim D-W, Lomaia E, Mayer J, et al. Asciminib (ASC) add-on to imatinib (IMA) demonstrates sustained high rates of ongoing therapy and deep molecular responses (DMRs) with prolonged follow-up in the ASC4MORE study. Oral presentation at: 65th ASH Annual Meeting & Exposition; December 9-12, 2023; San Diego, CA, and virtual. Oral 866.","DOI":"10.1182\/blood-2023-182100"},{"key":"2592_CR57","doi-asserted-by":"crossref","unstructured":"Cortes JE, Hughes T, Geissler J, Kim D-W, Lomaia E, Mayer J, et al. Efficacy and safety results from ASC4MORE, a randomized study of asciminib (ASC) add-on to imatinib (IMA), continued IMA, or switch to nilotinib (NIL) in patients (Pts) with chronic-phase chronic myeloid leukemia (CML-CP) not achieving deep molecular responses (DMRs) with \u22651 year of IMA. Oral presentation at: 64th ASH Annual Meeting & Exposition. December 10-13, 2022; New Orleans, LA, and virtual. Oral 80.","DOI":"10.1182\/blood-2022-167177"},{"key":"2592_CR58","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, et al. Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense. Blood Cancer J. 2023;13:58.","journal-title":"Blood Cancer J"},{"key":"2592_CR59","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97:1236\u201356.","journal-title":"Am J Hematol"},{"key":"2592_CR60","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","volume":"114","author":"S Soverini","year":"2009","unstructured":"Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009;114:2168\u201371.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02592-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02592-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02592-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T07:46:40Z","timestamp":1746517600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02592-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2592"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02592-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JEC: Novartis, Pfizer, and Bristol Myers Squibb: grants, consulting fees. FL: Bristol Myers Squibb, Incyte, and Celgene: consultancy, honoraria; Novartis: consultancy, honoraria, and research funding. DR: Novartis, Pfizer, and Incyte: personal fees. AH: Bristol Myers Squibb, Pfizer: institutional research support; Novartis and Incyte: institutional research support, personal honoraria. MB: Bristol Myers Squibb, Celgene, Pfizer, Incyte, and Novartis: consultancy and honoraria; AbbVie: consultancy. YTG: Pfizer, Johnson & Johnson, Amgen, MSD Pharma, EUSA Pharma, Roche, Bristol Myers Squibb, and AbbVie: honoraria. MCH: Novartis, Deciphera, Theseus, and Blueprint Medicines: consultancy; Deciphera: speakers bureau; Jonathan David Foundation, VA Merit Review Grant (I01BX005358), and NCI R21 grant (R21CA263400): partial salary support. Prior to 2019, MCH held an equity interest in MolecularMD. MCH holds multiple patents on the diagnosis and\/or treatment of gastrointestinal stromal tumors; 1 patent on treatment has been licensed by Oregon Health & Science University to Novartis. TPH: Novartis, Bristol Myers Squibb, and Enliven: consultancy, research funding. JJWMJ: Novartis and Bristol Myers Squibb: research funding; Incyte: speakers fee; AbbVie, Novartis, Pfizer, and Incyte: honoraria; AbbVie, Alexion, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen-Cilag, Olympus, Incyte, Sanofi Genzyme, Servier, Jazz, and Takeda: support for Apps for Care and Science nonprofit foundation, of which JJWMJ is president. PlC: Pfizer, Novartis, and Incyte: honoraria. HM: Chugai Pharma, Daiichi Sankyo, Eisai, Genmab, Guardant Health, Kyowa Kirin, Lilly Japan, Meiji Seika Kaisha, Miyarisan Pharmaceutical, Novartis, Otsuka Pharmaceutical, Pfizer, Shionogi, Rakuten Medical, Taiho Pharmaceutical, and Takeda: honoraria; Asahi Kasei Pharma, Chugai Pharma, Dainippon Sumitomo Pharma, Kyowa Kirin, Otsuka Pharmaceutical, Taiho Pharmaceutical, Nihonkayaku, and Teijin Pharma: research funding. KS: Novartis: research funding, honoraria. DJD: AbbVie, Novartis, Blueprint, and GlycoMimetics: grants; AbbVie, Novartis, Blueprint, and GlycoMimetics: research funding; AbbVie, Amgen, Autolus, Blueprint, Forty-Seven, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda: consulting; AbbVie, Amgen, Autolus, Blueprint, Forty-Seven, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda: personal fees. GSO, NP, and MC are employees of Novartis. MH is an employee and shareholder of Novartis. MJM\n                      :\n                      Bristol Myers Squibb, Takeda, and Pfizer: personal fees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}